What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Multi-antigen ribonucleic acid (RNA) vaccine for active immunization against tuberculosis administered as intramuscular injection”In the company’s words, NCT05547464 on ClinicalTrials.gov
- Tested for
- Tuberculosis
- Main trialPhase 1/2
- “This is a two-part randomized, placebo-controlled, observer-blind, safety and dose-finding Phase Ib/IIa study. This study will evaluate up to four dose levels of the BNT164 investigational vaccines (BNT164a1 and BNT164b1) to select a safe and tolerable dose in a three-dose schedule. This study includes: Part A (Phase Ib) and Part B (Phase IIa).”In the company’s words, NCT05547464 on ClinicalTrials.gov
Other drugs for Tuberculosis
- QuabodepistatOtsuka · Phase 3
- MTBVACBiofabri, S.L · Phase 3
- SudapyridineShanghai Jiatan Pharmatech Co., Ltd · Phase 3
- RBCG-N-RSVBiothervax SpA · Phase 2
- BNT164b1BioNTech · Phase 1/2
- JDB0131WestVac Biopharma Co., Ltd. · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | 12 Mar 2026 | Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers | |
| Phase 1Completed | 6 Jun 2025 | Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026